Drugs / GSK3844766A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04090658 | Sep 2019 → Jan 2020 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03814590 | Jan → Dec 2019 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-10-21 | GlaxoSmithKline | Results GSK presents positive clinical data on maternal and older adults RSV candidate vaccines gsk.com ↗
GSK today announced that its Respiratory Syncytial Virus (RSV) candidate vaccines for maternal immunisation (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in Phase I/II clinical studies. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-10-21 | GlaxoSmithKline | GSK presents positive clinical data on maternal and older adults RSV candidate vaccines gsk.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3844766A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04090658 ↗ |
| Known as | RSV_PreF3 Vaccine | “RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B” NCT04090658 ↗ |
| Modality | Vaccine | “investigational adjuvanted RSV vaccine” PMID 36641341 ↗ Jan 2023 |
| Route | Intramuscular | “by intramuscular (IM) injection” NCT04090658 ↗ |